Table 1.

Characteristics of 10,139 participants of the ACCORD study at baseline according to randomization to intensive versus standard glycemic control

Baseline CharacteristicsaIntensive TherapyStandard Therapy
NMean±SD or N (%)NMean±SD or N (%)
Age, yr507462±7506562±7
Women, %50741959 (39%)50651940 (38%)
Non-Hispanic white, %50743266 (64%)50653305 (65%)
Glycated hemoglobin, %50668.3±1.150538.3±1.1
BP, mm Hg50505046
 Systolic136±17137±17
 Diastolic75±1175±11
Cholesterol, g/dl50485035
 Total183±42183±41.6
 LDL105±34105±34
 HDL42±1242±12
 Triglycerides191±148190±149
Body mass index, kg/m507132±6506232±6
Waist circumference, cm5019107±145021107±14
Previous cardiovascular event, %50741804 (36%)50651755 (35%)
Baseline CKD status, %b50425022
 No CKD3173 (63%)3163 (63%)
 Stage 1626 (12%)641 (13%)
 Stage 2714 (14%)713 (14%)
 Stage 3a425 (8%)419 (8%)
 Stage 3b98 (2%)92 (2%)
 Stage 46 (0.1%)0
Baseline UACR, %50425022
 ≥30 μg/mg1247 (25%)1225 (24%)
 ≥300 μg/mg226 (5%)241 (5%)
 ≥1000 μg/mg97 (2%)99 (2%)
eGFR, ml/min per 1.73 m2b507483±17506584±17
UACR, μg/mgc504213.5 [6.8, 43.8]502213.6 [6.8, 44.4]
ACEI/ARB use, %50743428 (68%)50653445 (68.0%)
Thiazolidinedione use, %5074986 (19%)5065976 (19%)
  • ACCORD, Action to Control Cardiovascular Risk in Diabetes; UACR, urine albumin-to-creatinine ratio; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.

  • a Includes all ACCORD trial participants with at least some surveillance for primary outcome. Description of ACCORDION study population is available (43).

  • b eGFR was calculated using the CKD Epidemiology Collaboration Creatinine Equation. Stage 1 CKD: eGFR≥90 ml/min per 1.73 m2 and UACR≥30 μg/mg; stage 2 CKD: eGFR 60–89 ml/min per 1.73 m2 and UACR≥30 μg/mg; stage 3a CKD: eGFR 45–59 ml/min per 1.73 m2; stage 3b CKD: eGFR 30–44 ml/min per 1.73 m2; stage 4 CKD: eGFR 15–29 ml/min per 1.73 m2.

  • c Data are presented as median [IQR].